STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC OPTIC NEUROPATHY

• US 20090214485A1
• Filed: 02/25/2008
• Published: 08/27/2009
• Est. Priority Date: 02/25/2008
• Status: Active Grant

• Current Assignee: Stemedica Cell Technologies, Inc.
• Original Assignee: Irina Saburina, Natalie Gavrilova, Nikolay Mironov
• Inventors: GAVRILOVA, NATALIE, Mironov, Nikolay, Saburina, Irina
• Granted Patent: US 8,318,485 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses

Abstract

The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.

Claims

1. A method for treating a retinopathy or an optic neuropathy in a subject comprising:

administering ectodermal cells to the retinal tissue of said subject; and

intravenously administering mesenchymal cells to said subject.

2. The method of claim 1 wherein said retinopathy is diabetic retinopathy.

3. The method of claim 1 wherein said optic neuropathy is diabetic optic neuropathy.

4. The method of claim 2 wherein treating said retinopathy involves treating a disorder in the retinal tissue of a subject.

5. The method of claim 1 or 2, wherein said ectodermal cells are derived one or a combination of the group consisting of fetal neural tissue, adult neural tissue, and embryonic tissue.

6. The method of claim 1 or 2, wherein said mesenchymal cells are derived from postnatal tissue.

7. The method of claim 1 or 2, wherein said mesenchymal cells are derived from bone marrow.

8. The method of claim 6, wherein said postnatal tissue is selected from umbilical cord blood, placenta and combinations thereof.

9. The method of claim 1 or 2, wherein said retinal disorder is selected from diabetic retinopathy, macular degeneration, and retinal detachment.

10. The method of claim 1 or 2, wherein said ectodermal cells are injected by one or more of the administration routes selected from retrobulbarly, intravitreously, and subchoroidally.

11. A kit for treating a retinopathy or an optic neuropathy comprising:

a first container of isolated ectodermal cells in a pharmaceutically acceptable carrier;

a second container of isolated mesenchymal cells in a pharmaceutically acceptable carrier; and

printed instructions for treating said retinopathy or optic neuropathy.

12. The kit of claim 11, wherein said ectodermal cells are derived from at least one of fetal neural tissue, embryonic tissue and adult neural tissue.

13. The kit of claim 11, wherein said mesenchymal cells are derived from at least one of bone marrow, umbilical cord blood, and placenta.